Cite
MLA Citation
Alessio Cortellini et al.. “Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation.” Journal for immunotherapy of cancer, vol. 8, no. 2, 2020, p. . http://access.bl.uk/ark:/81055/vdc_100127561359.0x00002a